Browse the evidence

Unsaturated fatty acids, particularly omega-3 PUFAs like linoleic, oleic, and docosahexaenoic acid, stimulate insulin and glucagon secretion via activation of FFAR1 and FFAR4, improving glucose tolerance.

Incorporate unsaturated fatty acids, especially omega-3 PUFAs found in fish, nuts, and seeds, into your diet. These fatty acids activate FFAR1 and FFAR4 receptors, which can stimulate the release of insulin and glucagon, helping to regulate blood sugar levels. This is particularly beneficial for individuals with insulin resistance or type 2 diabetes.

Semaglutide improves NASH resolution in patients with stage 1-3 fibrosis but does not improve fibrosis or NASH resolution in patients with NASH-related cirrhosis.

Semaglutide can help resolve NASH in patients with early to moderate fibrosis, but it is not effective for reversing scarring in advanced cirrhosis, even if it helps with weight and metabolic markers.

Semaglutide achieves the highest response rate for NASH resolution without worsening fibrosis in clinical trials, but does not reverse fibrosis despite significant weight loss.

Semaglutide is currently the most effective drug for resolving NASH without worsening fibrosis, but it does not reverse existing fibrosis. It should be considered for patients who do not achieve goals with lifestyle changes alone, under medical supervision.

Quitting smoking after a new diagnosis of type 2 diabetes reduces the risk of cardiovascular disease and mortality, although the risk remains higher than in those who never smoked.

If you smoke, quit. Even after a diabetes diagnosis, stopping smoking lowers your risk of heart attack and death compared to continuing. While your risk might not drop to the level of someone who never smoked, it is much better than staying a smoker. Combine this with exercise for the best results.

Higher levels of abdominal subcutaneous adipose tissue (SAT) are positively associated with increased odds of adverse cardiometabolic risk factors, contradicting the hypothesis that abdominal SAT is metabolically protective.

If you carry excess weight in your abdomen, it matters whether it is visceral or subcutaneous, but both are linked to higher risks of high blood pressure, diabetes, and cholesterol issues. You cannot assume that 'soft' belly fat is safe just because it is not deep visceral fat. Reducing abdominal fat through lifestyle changes is necessary to lower these risks.

Dietary interventions that induce weight loss decrease circulating FGF-21 levels, with the magnitude of decrease being inversely proportional to carbohydrate content (very low carbohydrate diets causing the greatest reduction).

If you are maintaining weight loss, your body's FGF-21 levels will drop, which is a good sign of improved metabolic sensitivity. Eating fewer carbohydrates (Very Low Carb) causes a larger drop in FGF-21 than Low Fat or Low Glycemic Index diets. This suggests that reducing carbs may help resolve 'FGF-21 resistance' associated with obesity, potentially improving liver health.

Decreases in FGF-21 levels during weight loss maintenance are associated with improvements in hepatic insulin sensitivity, suggesting a resolution of FGF-21 resistance.

Improving your liver's sensitivity to insulin is a key goal of weight loss. This study suggests that as your FGF-21 levels drop (which happens with weight loss, especially low-carb diets), your liver becomes more responsive to insulin. This is a positive metabolic adaptation.

Dietary intervention (weight loss maintenance) increases fasting ghrelin levels and decreases chemerin levels, independent of macronutrient composition.

After weight loss, your body naturally increases hunger signals (ghrelin) and decreases inflammation markers (chemerin). This happens regardless of whether you eat low fat, low carb, or low glycemic index foods. This is a normal physiological response to weight loss.

Tirzepatide treatment (5-15 mg once weekly) reduces albuminuria (UACR) without causing adverse changes in estimated glomerular filtration rate (eGFR) in individuals with overweight or obesity, with or without type 2 diabetes.

If you have overweight or obesity, with or without type 2 diabetes, tirzepatide (a weekly injection) has been shown to improve kidney markers (specifically reducing albuminuria) without negatively impacting kidney filtration function. This benefit was observed across different doses (5-15 mg) over 72 weeks, alongside lifestyle changes. This suggests it may be a kidney-protective option for this population, particularly those with existing elevated albuminuria.

Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).

If you stop taking your GLP-1 medication (like Ozempic or Wegovy), you are likely to regain much of the weight you lost. More importantly, studies show that stopping these drugs increases your risk of heart attacks, strokes, and other cardiovascular events. If you are considering stopping due to side effects, talk to your doctor about adjusting the dose or switching medications rather than stopping abruptly, to protect your heart and maintain your weight loss.

Resistance exercise training in older adults preserves the capacity for myonuclear accretion (satellite cell fusion), indicating that the failure of aged muscle to hypertrophy is not caused by a lack of new nuclei or a myonuclear domain size ceiling.

If you are an older adult struggling to build muscle despite consistent resistance training, do not assume your muscle fibers have run out of capacity to grow. This research confirms that your muscles can still integrate new nuclei (via satellite cells) just as well as a younger person's. The bottleneck is likely not the structural capacity of the fiber, but rather the efficiency of protein synthesis machinery (ribosomes). Focus on high-intensity resistance training to maximize this preserved capacity.

Higher pre-diagnosis physical activity is associated with significantly lower all-cause mortality in postmenopausal women with early-stage breast cancer, but this benefit does not differ based on the number of cardiometabolic risk factors.

If you have had early-stage breast cancer, staying physically active before and after diagnosis is linked to a lower risk of dying from any cause. This benefit appears to apply whether you have metabolic risk factors (like high blood pressure or diabetes) or not. Aim for regular moderate-to-vigorous activity, such as brisk walking or recreational exercise, as measured in MET-hours per week.

Postprandial glycemic responses to identical meals are highly variable between individuals but predictable within individuals based on personal characteristics.

Recognize that your body's response to food is unique. While general guidelines exist, individual glycemic responses vary significantly. This supports the move towards personalized nutrition rather than relying on universal food labels like GI.

Combining direct patient mailings with in-clinic provider referrals significantly enhances the reach and representativeness of primary care behavioral weight loss interventions compared to passive or low-engagement strategies.

To successfully recruit patients into weight loss programs, primary care clinics should use a dual approach: send targeted mailings to eligible patients and actively encourage providers to make direct referrals during visits. This combination is more effective than either method alone, especially for reaching diverse populations. Providers should be supported with easy-to-use referral tools to minimize the time burden and ensure consistent outreach.

Resistance training improves body composition, strength, and redox balance in older hemodialysis patients, but low baseline hemoglobin (<11 g/dL) specifically impairs fat-free mass gains.

If you are on hemodialysis, resistance training is highly recommended and can improve your strength, body composition, and blood markers. However, if your hemoglobin is low (below 11 g/dL), you may not see the expected muscle growth despite training hard. In this case, treating your anemia is likely a prerequisite for maximizing muscle gains from exercise.

Tirzepatide, a GLP-1/GIP dual receptor agonist, significantly reduces HbA1c levels (up to 2.24%) and body weight (up to 11.2 kg) in patients with type 2 diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine in head-to-head trials.

Tirzepatide is a once-weekly injection for Type 2 Diabetes and obesity that significantly lowers blood sugar and promotes weight loss, often more effectively than other common medications like semaglutide or insulin. It works by mimicking hormones that regulate insulin and appetite. Common side effects like nausea are usually manageable by starting with a low dose and eating smaller, low-fat meals. Due to high costs, check for insurance coverage or assistance programs.

Individuals with unhealthy pre-pandemic lifestyle patterns (low diet quality, low physical activity) are more likely to improve their diet quality and lose weight during periods of high lifestyle disruption compared to those with healthy pre-pandemic patterns.

If you currently have unhealthy habits, a major life disruption (like a pandemic or job loss) might actually be the catalyst you need to improve your diet and lose weight, simply because you have more room to improve than someone who was already healthy. Focus on small, sustainable changes to diet quality and physical activity, as these are the key drivers of weight change during disruption.

Higher lifestyle disruption, measured by changes in diet quality, physical activity, sleep, snacking, and alcohol, is associated with greater bi-directional weight change (both loss and gain) compared to low disruption.

Major life changes tend to amplify your existing habits. If you are already active and eat well, disruption might not change much. If you are sedentary and eat poorly, disruption might lead to significant weight loss or gain. To manage weight during disruptions, focus on maintaining consistent physical activity and diet quality.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce systolic blood pressure, total stroke risk, and cardiovascular mortality in patients with type 2 diabetes or obesity.

If you have Type 2 Diabetes or Obesity and are at risk for heart disease or stroke, GLP-1 medications (like Semaglutide or Liraglutide) are strongly supported by evidence to lower your risk of heart attack, stroke, and cardiovascular death. Discuss these options with your doctor, especially if you have existing cardiovascular conditions.

Daily application of microcurrent (50-400 μA) for 3 hours alongside resistance training maximizes specific muscular architectural changes (pennation angle) and attenuates delayed onset muscle soreness (DOMS) compared to resistance training alone, without providing significant additional benefits on body composition or general performance metrics.

If you are a trained male lifting weights 3 times a week, adding 3 hours of daily microcurrent (50-400 μA) may help you recover faster from soreness and potentially optimize muscle fiber arrangement (pennation angle). However, do not expect it to make you stronger, jump higher, or build more muscle mass than resistance training alone. It is a recovery tool, not a growth driver.

Multi-receptor incretin drugs significantly reduce systolic and diastolic blood pressure, with Tirzepatide and Mazdutide showing the most substantial reductions, particularly in non-diabetic populations.

If you have high blood pressure along with overweight or obesity, multi-receptor incretin drugs can help lower both systolic and diastolic blood pressure. This effect is often stronger in people without type 2 diabetes. Discuss with your doctor if these medications could help manage your blood pressure as part of your overall treatment plan.

Programmatic facilitators for SERD adherence include group counseling, emotionally supportive clinical staff, and social network support, while barriers include product unpalatability, unrealistic expectations, and externalized stigma.

To maximize adherence to a SERD, patients should seek programs that offer group counseling, emotionally supportive staff, and a non-judgmental physical environment. Addressing product unpalatability and setting realistic weight loss expectations are key to overcoming common barriers.

Visceral adipose tissue (VAT) is the primary driver of cardiometabolic complications (hypertension, T2DM, dyslipidemia) through endocrine dysfunction, RAAS activation, and inflammation, rather than total body weight alone.

Stop relying on BMI to assess your health risk. Focus on reducing visceral fat through lifestyle changes, as this specific fat type drives heart disease and diabetes. Use waist-to-height ratio as a better metric than weight alone.

Semaglutide 2.4 mg is cost-effective for patients with BMI ≥ 30 kg/m² (ICER 18,459 EUR) but may not be cost-effective for patients with BMI ≥ 35 kg/m² (ICER 22,657 EUR) compared to the willingness-to-pay threshold of 20,000 EUR.

For patients with BMI ≥ 35 kg/m², semaglutide 2.4 mg may exceed the willingness-to-pay threshold for cost-effectiveness in Portugal, whereas it remains cost-effective for those with BMI ≥ 30 kg/m².